Neomycin indications and usage: Difference between revisions
Gerald Chi (talk | contribs) mNo edit summary |
Gerald Chi (talk | contribs) |
||
| Line 7: | Line 7: | ||
====Hepatic coma (portal-systemic encephalopathy)==== | ====Hepatic coma (portal-systemic encephalopathy)==== | ||
Neomycin sulfate has been shown to be effective adjunctive therapy in hepatic coma by reduction of the ammonia forming bacteria in the intestinal tract. The subsequent reduction in blood [[ammonia]] has resulted in neurologic improvement. | Neomycin sulfate has been shown to be effective adjunctive therapy in [[hepatic coma]] by reduction of the ammonia forming bacteria in the intestinal tract. The subsequent reduction in blood [[ammonia]] has resulted in neurologic improvement. | ||
To reduce the development of drug-resistant bacteria and maintain the effectiveness of Neomycin Sulfate Oral Solution and other antibacterial drugs, Neomycin Sulfate Oral Solution should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = NEO-FRADIN (NEOMYCIN SULFATE) SOLUTION [X-GEN PHARMACEUTICALS, INC.] | url =http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=aea1d3e4-604a-4680-91e2-cce6a128a1b5 | publisher = | date = | accessdate = }}</ref> | To reduce the development of drug-resistant bacteria and maintain the effectiveness of Neomycin Sulfate Oral Solution and other antibacterial drugs, Neomycin Sulfate Oral Solution should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = NEO-FRADIN (NEOMYCIN SULFATE) SOLUTION [X-GEN PHARMACEUTICALS, INC.] | url =http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=aea1d3e4-604a-4680-91e2-cce6a128a1b5 | publisher = | date = | accessdate = }}</ref> | ||
Latest revision as of 17:13, 7 January 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Indications and Usage
Hepatic coma (portal-systemic encephalopathy)
Neomycin sulfate has been shown to be effective adjunctive therapy in hepatic coma by reduction of the ammonia forming bacteria in the intestinal tract. The subsequent reduction in blood ammonia has resulted in neurologic improvement.
To reduce the development of drug-resistant bacteria and maintain the effectiveness of Neomycin Sulfate Oral Solution and other antibacterial drugs, Neomycin Sulfate Oral Solution should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.[1]
References
Adapted from the FDA Package Insert.